Programmed Death 1 Expression on CD4+ T Cells Predicts Mortality after Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 12, 2016, Pages 2172-2179

  Schade, Henning ^a,b   Sen, Sharon ^a,b   Neff, C Preston ^b   Freed, Brian M ^a,b   Gao, Dexiang ^c   Gutman, Jonathan A ^a,b   Palmer, Brent E ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Allogeneic stem cell transplantation; CD4+ T cells; Cord blood; Programmed death 1 (PD 1) expression

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; EFFECTOR CELL; FEMALE; HOSPITAL MORTALITY; HUMAN; HUMAN CELL; MALE; MEMORY T LYMPHOCYTE; MORTALITY RISK; PROTEIN EXPRESSION; SURVIVOR; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD; ALLOTRANSPLANTATION; CHEMISTRY; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CORD BLOOD STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVORS; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84992316520     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.08.007     Document Type: Article

References (60)

1. 1 Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13 (2013), 227–242.
2. 2 Odorizzi, P.M., Wherry, E.J., Inhibitory receptors on lymphocytes: insights from infections. J Immunol 188 (2012), 2957–2965.
3. 3 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
4. 4 Day, C.L., Kaufmann, D.E., Kiepiela, P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006), 350–354.
5. + T cells associated with reversible immune dysfunction. J Virol 81 (2007), 9249–9258.
6. 6 Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
7. 7 Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99 (2002), 12293–12297.
8. 8 Gallez-Hawkins, G.M., Thao, L., Palmer, J., et al. Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15 (2009), 872–880.
9. 9 Asakura, S., Hashimoto, D., Takashima, S., et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest 120 (2010), 2370–2378.
10. + T cells. Blood 117 (2011), 1030–1041.
11. 11 Ishida, Y., Agata, Y., Shibahara, K., Honjo, T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11 (1992), 3887–3895.
12. 12 Freeman, G.J., Long, A.J., Iwai, Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000), 1027–1034.
13. 13 Fife, B.T., Pauken, K.E., Eagar, T.N., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10 (2009), 1185–1192.
14. 14 Yamazaki, T., Akiba, H., Iwai, H., et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169 (2002), 5538–5545.
15. 15 Nakae, S., Suto, H., Iikura, M., et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176 (2006), 2238–2248.
16. 16 D'Addio, F., Riella, L.V., Mfarrej, B.G., et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 187 (2011), 4530–4541.
17. 17 Habicht, A., Dada, S., Jurewicz, M., et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol 179 (2007), 5211–5219.
18. 18 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
19. + T cell levels in humanized mice. J Immunol 190 (2013), 211–219.
20. 20 Velu, V., Titanji, K., Zhu, B., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458 (2009), 206–210.
21. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10 (2009), 29–37.
22. 22 Butler, N.S., Moebius, J., Pewe, L.L., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 13 (2012), 188–195.
23. + T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J Clin Invest 120 (2010), 3855–3868.
24. 24 Blazar, B.R., Carreno, B.M., Panoskaltsis-Mortari, A., et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171 (2003), 1272–1277.
25. 25 Saha, A., Aoyama, K., Taylor, P.A., et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122 (2013), 3062–3073.
26. 26 Norde, W.J., Maas, F., Hobo, W., et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 71 (2011), 5111–5122.
27. +) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 118 (2011), 4480–4488.
28. + T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 185 (2010), 3007–3018.
29. 29 Buhlmann, L., Buser, A.S., Cantoni, N., et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant 46 (2011), 1357–1362.
30. 30 Parkman, R., Cohen, G., Carter, S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 12 (2006), 919–927.
31. 31 Ochs, L., Shu, X.O., Miller, J., et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 86 (1995), 3979–3986.
32. + cell count and transplant-related mortality. Bone Marrow Transplant 41 (2008), 55–62.
33. 33 Kinter, A.L., Godbout, E.J., McNally, J.P., et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181 (2008), 6738–6746.
34. 34 Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
35. 35 Min, C.K., Kim, S.Y., Eom, K.S., et al. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse. Bone Marrow Transplant 37 (2006), 493–498.
36. 36 Mohty, M., Blaise, D., Faucher, C., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 106 (2005), 4407–4411.
37. 37 Holler, E., Kolb, H.J., Moller, A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990), 1011–1016.
38. 38 Krenger, W., Hill, G.R., Ferrara, J.L., Cytokine cascades in acute graft-versus-host disease. Transplantation 64 (1997), 553–558.
39. 39 Mumprecht, S., Schurch, C., Schwaller, J., Solenthaler, M., Ochsenbein, A.F., Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114 (2009), 1528–1536.
40. 40 Schnorfeil, F.M., Lichtenegger, F.S., Emmerig, K., et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol, 8, 2015, 93.
41. +) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J, 5, 2015, e330.
42. 42 Waki, K., Yamada, T., Yoshiyama, K., et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 105 (2014), 1229–1235.
43. + T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 10.18632/oncotarget.9316.
44. 44 Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J., Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 91 (1998), 3481–3486.
45. 45 Kim, D.H., Kim, J.G., Sohn, S.K., et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 125 (2004), 217–224.
46. 46 Aubert, R.D., Kamphorst, A.O., Sarkar, S., et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci USA 108 (2011), 21182–21187.
47. 47 Haspot, F., Fehr, T., Gibbons, C., et al. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood 112 (2008), 2149–2155.
48. 48 Lucas, C.L., Workman, C.J., Beyaz, S., et al. LAG-3, TGF-beta, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood 117 (2011), 5532–5540.
49. 49 Breton, G., Chomont, N., Takata, H., et al. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol 191 (2013), 2194–2204.
50. + T cell dysfunction in chronic viral infections. Curr Opin HIV AIDS 9 (2014), 446–451.
51. 51 Kanda, J., Chiou, L.W., Szabolcs, P., et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1664–1676 e1661.
52. 52 Jacobson, C.A., Turki, A.T., McDonough, S.M., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 565–574.
53. 53 Baron, F., Storer, B., Maris, M.B., et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 12 (2006), 1176–1187.
54. 54 Saber, W., Opie, S., Rizzo, J.D., Zhang, M.J., Horowitz, M.M., Schriber, J., Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119 (2012), 3908–3916.
55. 55 Mackall, C.L., Granger, L., Sheard, M.A., Cepeda, R., Gress, R.E., T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 82 (1993), 2585–2594.
56. 56 Williams, K.M., Hakim, F.T., Gress, R.E., T cell immune reconstitution following lymphodepletion. Semin Immunol 19 (2007), 318–330.
57. 57 Fry, T.J., Mackall, C.L., The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 174 (2005), 6571–6576.
58. 58 Villasboas, J.C., Ansell, S.M., Witzig, T.E., Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 7 (2016), 13260–13264.
59. 59 Herbaux C., Gauthier J., Brice P., et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC. Blood 2015:126.[Abstract 3979].
60. 60 Davids M.S., Kim H., Costello C.L., et al. A multicenter phase I/Ib study of ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic stem cell transplantation, Blood 2015:126 [Abstract 860].